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Atrial ﬁbrillation (AF) is strongly associated with cardioembolic stroke, and thromboprophylaxis is an established means of reducing stroke
risk in patients with AF. Oral vitamin K antagonists such as warfarin have been the mainstay of therapy for stroke prevention in patients with
AF. However, they are associated with a number of limitations, including excessive bleeding when not adequately controlled. Antiplatelet
agents do not match vitamin K antagonists in terms of their preventive efﬁcacy. Dual-antiplatelet therapy (clopidogrel and acetylsalicylic
acid) or combined antiplatelet–vitamin K antagonist therapy in AF has also failed to provide convincing evidence of their additional
beneﬁt over vitamin K antagonists alone. Novel oral anticoagulants, including the direct thrombin inhibitor dabigatran and direct Factor
Xa inhibitors such as rivaroxaban, apixaban, and edoxaban, have now been approved or are currently in late-stage clinical development
in AF. These newer agents may provide a breakthrough in the optimal management of stroke risk.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Previous estimates have suggested that atrial ﬁbrillation (AF) affects
over 2 million people in the USA and over 4 million across the
European Union.
1,2 Atrial ﬁbrillation is more common in older
people,
1 suggesting that it will become an ever-greater problem
in an increasingly ageing population.
Patients with AF are reported to have a ﬁve-fold increased risk
of stroke; moreover, compared with the other identiﬁed risk
factors for stroke (hypertension, heart failure, and coronary
heart disease), AF has the strongest association.
3 Atrial ﬁbrillation-
related stroke is cardiac in origin; thrombi form in the left atrial
appendage and embolize, causing ischaemic stroke.
2 Therefore,
antithrombotic therapy has become an established method of
preventing stroke in patients with AF.
This article reviews the current role of antithrombotic therapy
in patients with non-valvular AF, and examines the relative clinical
beneﬁt of current oral anticoagulant and antiplatelet therapies. The
latest developments in clinical trials of novel oral anticoagulants are
also reviewed.
Assessing the level of stroke risk in
atrial ﬁbrillation: risk stratiﬁcation
Numerous risk stratiﬁcation schemes have been developed to help
predict the level of stroke risk in patients with AF (low, moderate,
or high) and to manage them accordingly. Among the best known
is the CHADS2 scale, where points are attributed to the presence
of known risk factors: congestive heart failure, hypertension,
age ≥75 years, diabetes (1 point each), or previous stroke/transi-
ent ischaemic attack (TIA; two points, to reﬂect its greater associ-
ated risk).
4 Stratiﬁcation schemes (and management guidelines)
have also been developed by the joint Task Force of the American
College of Cardiology, American Heart Association, and European
Society of Cardiology (ACC/AHA/ESC),
2 and by the American
College of Chest Physicians (ACCP).
5 Because the various
schemes have been developed by independent groups over
several years, there is some heterogeneity between them; this
leads to considerable differences in a patient’s predicted level of
stroke risk, depending on the scheme used. An analysis of 12 pub-
lished risk stratiﬁcation schemes showed that, in a representative
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as ‘low risk’ varied from 7% to 42%, depending on the scheme
used.
4 A similar analysis by Lip et al.
6 found that, of a sample of
patients with AF from the Euro Heart Survey (n ¼ 1084), the per-
centage deﬁned as ‘low risk’ ranged from 9% to 48% across several
different schemes. Interestingly, the 9% relates to the ‘Birmingham
2009’ scheme, an adaptation of CHADS2 referred to as CHA2DS2-
VASc, which incorporates additional risk factors including vascular
disease, age 65–74 years, and female gender. In the CHA2DS2-
VASc scoring scheme, age ≥75 years is also assigned a greater
weight, i.e. two points.
6 In this 9% of patients, the incidence of
thromboembolism was 0% (compared with 1.4% using the
CHADS2 deﬁnition), suggesting that they were ‘truly’ low risk.
6
Taken together, these analyses indicate that perhaps as many as
90% of patients with AF can be classed as being at moderate-
to-high risk of stroke. A recent retrospective analysis of 73 538
patients with AF in Denmark assessed the predictive capability of
the new scheme and found the rate of thromboembolism
per 100 person-years in patients with a zero score was 1.67
[95% conﬁdence interval (CI) 1.47–1.89] for CHADS2 and 0.78
(95% CI 0.58–1.04) for CHA2DS2-VASc at 1 year.
7 In all risk cat-
egories except for CHA2DS2-VASc score equal to 0 there was a
reduction in risk with vitamin K antagonist (VKA) treatment.
Another study followed 79 844 patients with AF in the UK
General Practice Research Database for an average of 4 years.
8
In this study, the annual stroke rate per 100 person-years in
patients with a zero score was 1% for CHADS2 and 0.5% for
CHA2DS2-VASc. Interestingly, a small-scale Chinese study also
reported that, unlike CHADS2, the CHA2DS2-VASc score was
an independent predictor of left atrial thrombus in patients with
paroxysmal AF.
9 However, larger studies are needed to validate
this. Notably, the most recent ESC guidelines incorporate
CHA2DS2-VASc, recommending that CHADS2 be used for
initial assessments of the need for oral anticoagulation, with
CHA2DS2-VASc being invoked for further reﬁnement in patients
with a CHADS2 score of 0–1.
10
Thromboprophylaxiswithantithromboticagentsisassociatedwith
an increased risk of bleeding, and guidelines recommend that individ-
ual patients’ bleeding risks should also be considered before starting
antithrombotic treatment.
2,10–12Because manyofthe riskfactorsfor
stroke and bleeding are similar, the rate of major haemorrhage is
higher in patients with higher CHADS2 scores,
6,13,14 and so an accu-
rate tool for assessing individual bleeding risk is of value to help guide
treatment.Acomparisonofbleedingriskschemesusingatrialcohort
of 7329 patients with AF found the HAS-BLED scheme to have the
best predictive value.
14 The risk factors included in the HAS-BLED
scheme (given 1 point each) are hypertension, abnormal renal or
liverfunction,historyofstroke,historyofbleedingorbleedingpredis-
position,labile internationalnormalized ratios(INRs),age .65years,
and concomitant drug use or alcohol abuse. The predictive ability of
the HAS-BLED scheme has also been compared with the alternative
scheme, HEMORR2HAGES, in a Danish registry of 118 584 patients
withAF.
15HEMORR2HAGES,likeHAS-BLED,isapointschemewith
two points assigned for a prior bleed and one point for other risk
factors including: hepatic or renal disease, ethanol abuse, malignancy,
older (age .75 years), reduced platelet count or function, hyperten-
sion (uncontrolled), anaemia, genetic factors, excessive fall risk, and
stroke.
16 The two schemes had a similar ability to predict the rate
of hospitalization or death from major bleeding in 1 year, with both
schemes demonstrating increasing bleeding rates with increasing
score.
15 The authors concluded, however, that the simplicity of
HAS-BLED was advantageous as it could be used more easily in clini-
cal practice. The Canadian Cardiovascular Society (CCS) and ESC
2010 guidelines both advocate the use of the HAS-BLED scheme,
with HAS-BLED score ≥3 deemed to indicate high risk of bleeding,
and caution and regular review recommended regardless of
whether the patient is treated with an oral anticoagulant or acetylsa-
licylic acid (ASA).
10,12
Oral anticoagulant therapy:
vitamin K antagonists
Until recently, VKAs such as warfarin were the only approved means
of oral anticoagulant therapy for stroke prevention in AF. According
to ACC/AHA/ESC 2006/2011 and ACCP 2008 guidelines, patients
with moderate-to-high risk of stroke should be considered for
stroke prophylaxis with a VKA.
2,5,11 The ESC 2010 guidelines
recommend that patients with a CHADS2 score ≥2s h o u l d
receive oral anticoagulation therapy; patients with a CHADS2
score of ,2 should be assessed using CHA2DS2-VASc.
10 Those
with a CHA2DS2-VASc score of 1 may receive either oral anticoa-
gulation therapy or ASA (with oral anticoagulation the preferred
option of the two), and patients with a CHA2DS2-VASc score of
0 may receive either ASA or no antithrombotic therapy—with
the guidelines also stating that no antithrombotic therapy is the pre-
ferred choice in these patients.
10
In 2007, Hart et al.
17 published the ﬁndings of a comprehensive
meta-analysis of data from 29 randomized clinical trials assessing
the efﬁcacy and safety of antithrombotic agents (including VKAs)
in patients with non-valvular AF. Reviewing six trials that compared
a VKA with placebo or control, the meta-analysis found that
adjusted-dose warfarin reduced the relative risk (RR) of stroke
by 64% (95% CI 49–74) vs. placebo or control (53 events in
2396 patient-years vs. 133 events in 2207 patient-years)
(Figure 1A). When ischaemic stroke alone was analysed, the RR
reduction with adjusted-dose warfarin was 67% (95% CI 54–77).
17
Compared with placebo or control, a 26% (95% CI 3–43)
reduction in all-cause mortality was also seen with adjusted-dose
warfarin (110 vs. 143 deaths).
Vitamin K antagonist therapy has considerable limitations, one
of which is its association with increased bleeding. The 2007
meta-analysis showed that dose-adjusted warfarin increased the
RR of intracranial haemorrhage by 128% compared with ASA;
the difference in absolute risk between warfarin and ASA was
small (0.2% per year), but was reported as being statistically signiﬁ-
cant.
17 It has been suggested that rates of haemorrhage in younger
non-inception trial cohorts underestimate warfarin-related bleed-
ing in practice.
13 In a cohort of patients with AF receiving warfarin
who were ≥65 years of age, the rate of intracranial haemorrhage
was 2.5%.
13 The ﬁrst 90 days of warfarin, age ≥80 years, and INR
≥4.0 were associated with an increased risk of major haemor-
rhage. Warfarin use was the cause of 15% of the drug-related
adverse events in a cohort of 1247 long-term care residents.
18 In
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been found to be associated with anticoagulation therapy, with
98% of these patients receiving warfarin treatment.
19
Vitamin K antagonists also have a delayed onset of action; in the
ﬁrst few days, heparin bridging therapy is required until the anti-
coagulant effect of the VKA is established.
20 Vitamin K antagonists
are also associated with variable dose–response proﬁles: reasons
for this include environmental and hereditary factors (body weight,
age, and genetic polymorphisms), and interactions with foods and
drugs.
20 The narrow therapeutic window of VKAs (INR of pro-
thrombin times ranging between 2.0 and 3.0 in patients with AF)
20
is another limitation. Patients receiving VKA therapy, therefore,
need regular coagulation monitoring and dose adjustment.
Thus, VKAs are often underused in the clinical setting. For
example, a retrospective US cohort study of hospitalized patients
with AF (n ¼ 945) found that, although 86% of patients were
classed as being at high risk of stroke, only 55% were given a
VKA.
21 More surprisingly, 21% of high-risk patients did not
receive a VKA or ASA. There are similar ﬁndings regarding the
suboptimal use of VKAs in those at high risk of stroke in the
out-of-hospital setting.
22
Antiplatelet therapy
Acetylsalicylic acid has been widely used as an agent for stroke
prophylaxis in patients with AF. Until recently, guidelines rec-
ommended ASA therapy only in patients with non-valvular AF
who are considered at low risk of stroke, or in whom VKA
therapy is contraindicated.
2,5 However, the ESC 2010 guidelines
and the ACC Foundation/AHA/Heart Rhythm Society (ACCF/
AHA/HRS) focussed update to the ACC/AHA/ESC 2006 guide-
lines include a role for clopidogrel use in conjunction with ASA,
suggesting that this dual-antiplatelet combination could be con-
sidered for stroke prevention in patients for whom oral anticoagu-
lation therapy may be unsuitable.
10,23
A number of studies have evaluated the efﬁcacy of antiplatelet
agents, principally ASA, in reducing thromboembolism in patients
with AF. In their meta-analysis, Hart et al.
17 reported a 19%
(95% CI –1 to 35) reduction in the RR of stroke in patients
with AF treated with ASA compared with placebo or no treatment
(179 events in 3432 patient-years vs. 209 events in 3302 patient-
years). However, this reduction in risk was not statistically signiﬁ-
cant. Furthermore, the dose of ASA varied widely from 50 to
1300 mg per day in the studies included in the meta-analysis
with most of the beneﬁcial effects of ASA driven from the
Stroke Prevention in Atrial Fibrillation (SPAF) I study, which uti-
lized a 325 mg dose.
10,24 In contrast, the Japan Atrial Fibrillation
Stroke Trial compared an ASA dose of 150–200 mg per day
with no treatment in 871 patients with AF.
25 This trial was
stopped early due to a non-signiﬁcant increase in the risk of
major bleeding of 1.6% with ASA, compared with 0.4% in the
no-treatment group. Also, the greater number of primary endpoint
events (cardiovascular death, symptomatic brain infarction, or TIA)
in the ASA arm (3.1% per year) compared with no-treatment
group (2.4% per year) meant that treatment with ASA was unlikely
to be superior to no treatment.
A comparison of antiplatelets (including clopidogrel, triﬂusal,
and indobufen as well as ASA) with VKA therapy in the
meta-analysis by Hart et al. revealed that adjusted-dose warfarin
reduced the RR of all stroke by 37% (95% CI 23–48) compared
with antiplatelet therapy (180 vs. 282 events in 8946 patient-years)
(Figure 1B).
17 The modest effect of antiplatelet agents on stroke
risk may be more due to the inhibition of platelet thrombi in the
carotid and cerebral arteries than the inhibition of cardiogenic
A Study, year B Study, year
Adjusted-dose warfarin compared
with placebo or control
AFASAK I, 1989; 1990
SPAF I, 1991
BAATAF, 1990
CAFA, 1991
SPINAF, 1992
EAFT, 1993
Adjusted-dose warfarin compared
with antiplatelet agents
AFASAK I, 1989; 1990
AFASAK II, 1998
Chinese ATAFS, 2006
EAFT, 1993
PATAF, 1999
SPAF II, 1994
SIFA, 1997
ACTIVE-W, 2006
NASPEAF, 2004
Age £75 years
Age >75 years
Acetylsalicylic acid trials (n = 8)
All antiplatelet trials (n = 11)
All trials (n = 6)
Favours warfarin Favours placebo
or control
100% 50% –50% 0 –100%
Favours warfarin Favours antiplatelet
100% 50% –50% 0 –100%
Relative risk reduction
(95% CI)
Relative risk reduction
(95% CI)
Figure 1 Relative effects of antithrombotic therapies on all stroke from randomized trials in patients with atrial ﬁbrillation: (A) adjusted-dose
warfarin compared with placebo or no treatment, (B) adjusted-dose warfarin compared with antiplatelet agents. Details of the analyses
conducted are described in the original publication by Hart et al.
17 Figures reproduced with permission from Annals of Internal Medicine.
J.-P. Bassand 314thrombi that occur in AF.
26 However, it is likely that the lower
bleeding risk with antiplatelet agents compared with that of
VKAs (albeit at the cost of reduced efﬁcacy) remains their key
attraction.
Are combination therapies a viable
alternative to vitamin K antagonist
or antiplatelet monotherapy
in atrial ﬁbrillation?
Dual-antiplatelet therapy
In previous years, the relative efﬁcacy and safety proﬁles of dual-
antiplatelet therapy (ASA and clopidogrel) have been assessed in
patients with AF (Table 1). In the Atrial ﬁbrillation Clopidogrel
Trial with Irbesartan for prevention of Vascular Events (ACTIVE)
W study, patients with electrocardiogram-conﬁrmed AF and at
least one risk factor for stroke were randomized to receive
clopidogrel with ASA or VKA therapy (target INR 2.0–3.0).
27
Clopidogrel plus ASA therapy was associated with signiﬁcantly
more major vascular events [stroke, non-central nervous system
(CNS) systemic embolism, myocardial infarction, or vascular
death] than VKA therapy (P ¼ 0.0003) (Table 1). Rates of major
bleeding were similar between the two groups, but there were
signiﬁcantly more cases of minor bleeding in the clopidogrel plus
ASA group (P ¼ 0.0009). The study was stopped early owing to
the clear superiority of VKA therapy.
Acetylsalicylic acid is prescribed in patients with AF who cannot
(or will not) tolerate VKAs.
28 The ACTIVE A trial compared the
efﬁcacy and safety of clopidogrel plus ASA vs. placebo plus ASA
in patients with AF who were at increased risk of stroke, but
who were considered unsuitable for VKA therapy (Table 1).
28 In
the clopidogrel plus ASA group, there were signiﬁcantly fewer
major vascular events compared with the placebo plus ASA
group (P ¼ 0.01) (Table 1). This effect on the primary endpoint
was mainly due to the reduced incidence of stroke. However,
major bleeding occurred more frequently in patients taking clopi-
dogrel than those receiving placebo (P , 0.001), with the most
common site of bleeding being the gastrointestinal tract. Clopido-
grel plus ASA increased the risk of major extracranial bleeding by
51% and the risk of major intracranial bleeding by 87%. There was
no signiﬁcant difference in net clinical beneﬁt (major vascular
events plus major bleeding) between the two groups.
Antiplatelet plus vitamin K antagonist
therapy
Studies combining VKAs with antiplatelet therapy in patients with
AF have also been conducted. Their main aim was to assess
whether combination therapy enabled the intensity of anticoagula-
tion to be reduced, lessening the likelihood of excessive bleeding
and the need for regular monitoring, while maintaining protective
efﬁcacy (Table 2).
The SPAF III trial compared ASA and ﬁxed-dose warfarin (to
maintain INR 1.2–1.5) with adjusted-dose warfarin alone (target
INR 2.0–3.0) in patients with non-valvular AF at high risk of
thromboembolism.
29 The trial was stopped early, owing to a
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Table 2 Studies of combined oral anticoagulant and antiplatelet therapy in patients with atrial ﬁbrillation
Study Population Treatment groups Primary efﬁcacy
endpoint
Major/severe bleeding
endpoint
Key ﬁndings P value (if given)
SPAF III
29 Pts (n ¼ 1044) with NVAF and
(≥1 of): LV dysfunction or
CHF; hypertension;
ischaemic stroke, TIA, or SE;
female; and age . 75 yrs
(1) ASA 325 mg/day + low-dose
warfarin (INR 1.2–1.5)
Ischaemic stroke,
SE
Fatal, life-threatening or
potentially life-threatening,
bleeding that leads to
reoperation, or moderate
or severe blood loss
30
Primary events (annual rate): 7.9% (low-dose
warf + ASA) vs. 1.9% (adjusted-dose warf)
P , 0.0001
(2) Adjusted-dose warfarin
(INR 2–3)
Major bleeding (annual rate): 2.4% (low-dose
warf + ASA) vs. 2.1% (adjusted-dose warf)
NS
AFASAK 2
31 Pts (n ¼ 677) with NVAF,
≥18 yrs
(1) Warfarin (1.25 mg/day)
(2) Warfarin (1.25 mg/day) +
ASA (300 mg/day)
(3) ASA (300 mg/day)
(4) Adjusted-dose warfarin (INR
2–3)
All stroke, SE Fatal, life-threatening or
potentially life-threatening,
requiring surgery or blood
transfusion
Primary events (after 1 yr): 5.8% (low-dose warf),
7.2% (low-dose warf + ASA), 3.6% (ASA),
2.8% (adjusted-dose warf)
P ¼ 0.67
Major bleeding events: 3 (low-dose warf), 1
(warf + ASA), 5 (ASA), 4 (adjusted-dosewarf)
Edvardsson
et al.
32
Pts (n ¼ 668) with NVAF and
no prior stroke/TIA
(1) Warfarin (1.25 mg/
day) + ASA (75 mg/day)
(2) No treatment (control)
All stroke Bleeding warranting exclusion
from the trial
(protocol-speciﬁed)
All stroke: 9.6% (warf + ASA) vs. 12.3% (control) HR 0.78 (95% CI
0.49–1.23),
P ¼ 0.28
Reported bleeds: 5.7% (warf + ASA) vs. 1.2%
(control)
HR 5.11 (95% CI
1.75–15.0),
P ¼ 0.003
FFAACS
33 Pts with NVAF and: (1) history
of TE or (2) age .65 yrs plus
1 of: hypertension, CHF, or
LV dysfunction
Adjusted-dose ﬂuindione (INR 2–
2.6) plus (1) ASA (100 mg/day)
or (2) Placebo
Stroke, SE, MI, or
vascular death
Requiring speciﬁc treatment
(e.g. transfusion) or
hospitalization
Primary events (per 100 pt-yrs): 7.93
(ﬂuin + ASA) vs. 2.87 (ﬂuin)
P ¼ 0.21
Severe bleeds (events per 100 pt-yrs): 4.8
(ﬂuin + ASA) vs. 1.4 (ﬂuin)
P ¼ 0.35
NASPEAF
34 n ¼ 1209
High risk: (1) Pts with
NVAF + prior embolism and
(2) pts with mitral stenosis with/
without prior embolism
Intermediate risk: (1) Triﬂusal
(600 mg/day); (2) VKA (INR
2–3); and (3) Triﬂusal (600 mg/
day) + VKA (INR 1.25–2)
Stroke, TIA, SE, or
vascular death
Severe: requiring hospital
admission, blood
transfusion, or surgery
Intermediate risk (events per 100 pt-yrs):
Primary: 3.82 (triﬂ), 2.70 (VKA), 0.92
(combined)
Severe bleeding: 0.35 (triﬂ), 1.80 (VKA),
0.92 (combined)
P , 0.05
(combined vs.
others)
All others: intermediate risk High risk: (1) VKA (INR 2–3) and
(2) Triﬂusal (600 mg/day) +
VKA (INR 1.4–2.4)
NS
Net beneﬁt (primary outcome and severe
bleeding): 3.82 (triﬂ), 3.78 (VKA), 1.48
(combined)
P , 0.05
(combined vs.
others)
High risk (events per 100 pt-yrs): Primary: 4.76
(VKA) vs. 2.44 (combined)
P , 0.05
Severe bleeding: 2.13 (VKA) vs. 2.09 (combined) NS
Net beneﬁt: 5.58 (VKA) vs. 3.84 (combined) NS
NASPEAF
follow-up
35
Pts (n ¼ 400) from NASPEAF
2004 study
34 + new pts
(n ¼ 174)
(1) VKA (INR 2–3)
(2) VKA (INR 1.9–2.5) + triﬂusal
(600 mg/day)
(3) VKA (INR 1.9–2.5) + triﬂusal
(300 mg/day)
(4) VKA (INR 1.9–2.5) + ASA
(100 mg/day)
Stroke, SE, ACS,
sudden death,
death ≤30 days
after an event
or severe
bleeding
See NASPEAF 2004 deﬁnition Primary events (per 100 pt-yrs): 2.86 (VKA), 1.36
(VKA + triﬂ 600 mg/day), 2.67 (VKA + triﬂ
300 mg/day), 2.83 (VKA + ASA)
P ¼ 0.039
(VKA + triﬂ
600 mg/day vs.
VKA)
Severe bleeding (events per 100 pt-yrs): 2.47
(VKA), 1.51 (VKA + triﬂ 600 mg/day), 1.33
(VKA + triﬂ 300 mg/day), 6.6 (VKA + ASA)
P ¼ 0.008
(VKA + ASA
vs. all others)
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6signiﬁcantly higher rate of ischaemic stroke and systemic embolism
in the combination group compared with warfarin alone (P ,
0.0001). There was no difference in major bleeding rates
between the groups. The Copenhagen Atrial Fibrillation, Aspirin,
and Anticoagulation (AFASAK 2) study, assessing the efﬁcacy and
safety of ﬁxed, low-dose warfarin with (or without) ASA compared
with ASA or adjusted-dose warfarin (INR 2.0–3.0) alone, was also
stopped early in light of the SPAF III ﬁndings.
31 No signiﬁcant differ-
ence in the cumulative rate of primary events (stroke or systemic
thromboembolic event) between the different treatment groups
was reported after 1, 2, or 3 years (P ¼ 0.67; Table 2). A higher
cumulative rate of bleeding was seen with warfarin after 3 years
(P ¼ 0.003). The investigators in both trials concluded that the
very low intensity of anticoagulation achieved with the combi-
nation therapy did not justify replacing the current adjusted-dose
VKA therapy.
29,31 A later study compared low-dose warfarin plus
ASA with no treatment in patients with AF who were not rec-
ommended anticoagulation therapy (described as ‘low-to-medium
risk’).
32 They also reported that combination therapy did not
signiﬁcantly reduce stroke risk, but was associated with higher
bleeding rates (Table 2). However, the results may also have
been affected by the lower than planned number of eligible
patients included.
Other studies such as Fluindione, Fibrillation Auriculaire, Aspirin
etContrasteSpontane ´ (FFAACS),andNationalStudyforPrevention
of Embolism in Atrial Fibrillation (NASPEAF) have also assessed the
efﬁcacy and safety of combination therapy using higher-intensity
anticoagulation than above (Table 2).
33–36 However, their overall
ﬁndings are inconclusive; some report a positive effect of combined
therapy compared with VKA monotherapy on the different end-
points, while others report no difference or a negative effect
(Table 2).
In summary, the efﬁcacies of clopidogrel plus ASA or antiplatelet
plus VKA therapies in such trials do not provide strong evidence
that they should replace VKA monotherapy in patients with non-
valvular AF. Future studies with newer antiplatelet agents such as
prasugrel and ticagrelor might force a reassessment; however,
this is purely speculative.
New oral anticoagulants
in development
Given the inherent limitations of VKA therapy, and the lack of a
suitable alternative dual-antiplatelet or combined antiplatelet—
VKA strategy, attention has switched to developing new oral anti-
coagulants. Rather than acting on several different factors in the
coagulation cascade, as VKAs do, new oral anticoagulants are
designed to target a speciﬁc component of the cascade. Oral
agents with little potential for food or drug interactions, and
which can be administered in ﬁxed doses without routine
coagulation monitoring, have the potential to simplify long-term
anticoagulant therapy.
There are currently many novel oral anticoagulants that have
recently been approved or are in the advanced stages of clinical
research in the AF setting. Here, those agents with completed
or ongoing phase II and III trials in patients with AF are discussed.
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Table 3 Summary of key phase III completed or ongoing trials with novel oral anticoagulants
Study Population Treatment groups Primary efﬁcacy and safety
endpoints
Key ﬁndings
RE-LY
37,38 Pts (n ¼ 18113) with NVAF
and ≥1 of:
(1) Dabigatran etexilate 110 mg
bid (blinded)
Primary efﬁcacy endpoint: composite of
stroke and SE
Primary efﬁcacy endpoint:
110 mg bid vs. warf: RR 0.90 (95% CI: 0.74–1.10);
P (superiority) ¼ 0.30
150 mg bid vs. warf: RR 0.65 (95% CI: 0.52–0.81);
P (superiority) , 0.001
Randomized, open-label,
parallel-group, multicentre
non-inferiority trial
Prior stroke/TIA, age ≥75 yrs,
symptomatic heart failure (NYHA
class ≥2), LVEF , 40%; orage 65–
74 yrs + diabetes mellitus,
hypertension, or CAD
(2) Dabigatran etexilate 150 mg
bid (blinded)
Primary safety outcome: major bleeding
(Hb drop ≥2 g/dL, transfusion ≥2
units of blood, bleeding in critical area
or organ, life-threatening bleeding)
(3) Open-label warfarin (INR
2–3) Primary safety outcome:
110 mg bid vs. warf: RR 0.80 (95% CI: 0.70–0.93);
P (superiority) ¼ 0.003
150 mg bid vs. warf: RR 0.93 (95% CI: 0.81–1.07);
P (superiority) ¼ 0.32
ROCKET AF
39,40
Randomized, double-blind,
double-dummy,
parallel-group, multicentre
non-inferiority trial
Pts (n ¼ 14264) with NVAF and prior
stroke/TIA or SE, or ≥2 of:
CHF or LVEF ≤35%, hypertension,
age ≥75 yrs, diabetes mellitus
a
(1) Double-blind rivaroxaban
20 mg od (15 mg od for pts
with creatinine clearance 30–
49 mL/min)
(2) Double-blind warfarin
(INR 2–3)
Primary efﬁcacy endpoint: composite of
stroke and SE
Primary safety outcome: major and
non-major clinically relevant bleeding
(major: clinically overt bleeding
associated with fatal outcome,
involving a critical site, Hb drop
≥2 g/dL, transfusion ≥2 units of
packed RBCs or whole blood)
Primary efﬁcacy endpoint:
Per protocol population, on treatment: rivaroxaban vs.
warf: HR 0.79 (95% CI: 0.66–0.96); P (non-inferiority)
, 0.001
Safety population, on treatment: rivaroxaban vs. warf: HR
0.79 (95% CI: 0.65–0.95); P (superiority) ¼ 0.02
Intention-to-treat: rivaroxaban vs. warf: HR 0.88 (95% CI:
0.74–1.03); P (non-inferiority) , 0.001
Primary safety outcome: rivaroxaban vs. warf: HR 1.03
(95% CI: 0.96–1.11) P (superiority) ¼ 0.44
ARISTOTLE
41,42
Randomized, double blind,
double-dummy, active
(warfarin) controlled
non-inferiority trial
Pts (n ¼ 18201) with NVAF and ≥1
of:
Prior stroke/TIA or SE, age ≥75 yrs,
symptomatic CHF or LVEF ≤40%,
diabetes mellitus, hypertension
(1) Double-blind apixaban 5 mg
bid (2.5 mg bid for pts with ≥2
of the following at baseline: age
≥80 yrs, body weight ≤60 kg,
serum creatinine ≥1.5 mg/dL)
(2) Double-blind warfarin
(INR 2–3)
Primary efﬁcacy endpoint: composite of
stroke and SE
Primary safety outcome: major bleeding
(clinically overt bleeding plus ≥1 of:
Hb drop ≥2 g/dL; transfusion of ≥2
units of packed RBCs; fatal bleeding or
bleeding that occurs in ≥1 critical site)
Primary efﬁcacy endpoint: apixaban vs. warf: HR 0.79
(95% CI: 0.66–0.95); P (superiority) ¼ 0.01
Primary safety outcome: apixaban vs. warf: HR 0.69 (95%
CI: 0.60–0.80); P , 0.001
AVERROES
43,44
Randomized, double-blind,
double-dummy superiority
trial
Pts (n ¼ 5599) aged ≥50 yrs with
NVAF unsuitable for VKA use and
≥1 of:
Prior stroke/TIA, age ≥75 yrs, heart
failure (NYHA class ≥2), or LVEF
≤35%, diabetes mellitus,
hypertension, PAD
(1) Double-blind apixaban 5 mg
bid (or 2.5 mg bid – see
ARISTOTLE)
(2) Double-blind ASA
(81–324 mg/day)
See ARISTOTLE Primary efﬁcacy endpoint: apixaban vs. ASA: HR 0.45
(95% CI: 0.32–0.62]; P , 0.001
Primary safety outcome: apixaban vs. ASA: HR 1.13 (95%
CI: 0.74–1.75); P ¼ 0.57
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8Phase III trials of the novel oral anticoagulants are also summarized
in Table 3.
Oral direct thrombin inhibitors
Factor IIa (thrombin) is responsible for converting ﬁbrinogen into
ﬁbrin and thus represents the ﬁnal step in the coagulation
pathway. In recent years, novel, oral direct thrombin inhibitors
have been developed, some of which have been extensively
evaluated in patients with AF.
Ximelagatran
Ximelagatran was the ﬁrst oral anticoagulant to become available
since the introduction of warfarin, and was approved in 22
countries (mostly European, but also including Argentina, Brazil,
Hong Kong, and Indonesia) for the prevention of venous throm-
boembolism following total hip or knee replacement.
46,47 In AF,
the Stroke Prevention using an Oral Thrombin Inhibitor in Atrial
Fibrillation (SPORTIF) trials III and V demonstrated that ximelaga-
tran was at least as effective as warfarin (INR 2.0–3.0) for the
primary outcome (all stroke or systemic embolism). No difference
was seen between the treatment groups for rates of major bleed-
ing.
48,49 However, clinical development of ximelagatran was
stopped and it was withdrawn from the market following reports
of hepatotoxicity.
46,47,50 Despite this, it demonstrated the feasi-
bility of using an oral, fast-acting anticoagulant that did not
require routine coagulation monitoring in patients with AF.
50
Dabigatran
Dabigatran is an oral direct thrombin inhibitor provided as a
prodrug, dabigatran etexilate. Dabigatran has a bioavailability of
around 7% after oral administration of dabigatran etexilate,
51 and
a half-life of up to 17 h.
52 More than 80% of systemically available
dabigatran is excreted renally.
51
In the phase III Randomized Evaluation of Long-Term Anticoagu-
lation Therapy (RE-LY) non-inferiority trial,
37,38 patients with non-
valvular AF (n ¼ 18 113) were randomized to receive two ﬁxed
doses of dabigatran [110 mg twice daily (bid) or 150 mg bid] in a
blinded fashion, while the warfarin dose-adjusted (INR 2.0–3.0)
arm was open label. The mean CHADS2 score at baseline was
2.1, and when baseline scores were grouped into three categories
(0–1, 2, and 3–6), approximately one-third of patients fell into
each category. Approximately 20% of patients had experienced a
previous stroke or TIA at baseline. The median follow-up duration
was 2 years. The 150 mg bid dose showed superior efﬁcacy to war-
farin for the primary endpoint of stroke or systemic embolism
[1.11 vs. 1.71% per year; RR 0.65 (95% CI 0.52–0.81); P , 0.001
for superiority], and the 110 mg bid dose achieved non-inferiority
[1.54 vs. 1.71% per year; RR 0.90 (95% CI 0.74–1.10); P , 0.001
for non-inferiority], but not superiority (Table 3). Similar rates of
all-cause mortality were seen across the groups. A greater
number of myocardial infarctions was seen with both the
110 mg and 150 mg bid dose of dabigatran (98 and 97 events,
respectively) compared with warfarin (75 events), although this
did not reach statistical signiﬁcance [110 mg vs. warfarin: RR 1.29
(95% CI 0.96–1.75; P ¼ 0.09); 150 mg vs. warfarin: RR 1.27 (95%
CI 0.94–1.71); P ¼ 0.12]. The rate of major bleeding was
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farin [2.87 vs. 3.57% per year; RR 0.80 (95% CI 0.70–0.93); P ¼
0.003], and the higher dose showed no signiﬁcant difference
from warfarin [3.32 vs. 3.57% per year; RR 0.93 (95% CI 0.81–
1.07); P ¼ 0.32] (Table 3).
37,38 A signiﬁcantly higher rate of major
gastrointestinal bleeding was seen with dabigatran 150 mg bid vs.
warfarin
(P , 0.001). Dyspepsia was also signiﬁcantly more common in
patients receiving dabigatran compared with warfarin (P , 0.001).
Discontinuation rates were signiﬁcantly higher in the dabigatran
groups vs. the warfarin group at 1 year [15% (110 mg bid) and
16% (150 mg bid) vs. 10% (warfarin); P , 0.001] and at 2 years
[21% (110 and 150 mg bid) vs. 17% (warfarin); P , 0.001]. The
authors reported a signiﬁcant net clinical beneﬁt outcome (major
vascular events, major bleeding, and death) with the 150 mg bid
dose compared with warfarin [7.11 vs. 7.91% per year; RR 0.90
(95% CI 0.82–0.99); P ¼ 0.02]. The results of the RE-LY study
formed the basis of the approval of dabigatran 150 mg bid dose
for the prevention of stroke and systemic embolism in patients
with AF by the Food and Drug Administration (FDA).
53
However, the FDA also approved a 75 mg bid dose for patients
with poor renal function (creatinine clearance of 15–30 mL/min),
based on pharmacokinetic modelling data, but decided against
approving the 110 mg bid dose.
54
Following FDA approval, dabigatran was the focus of an
ACCF/AHA/HRS update to the ACC/AHA/ESC 2006 guide-
lines.
55 The update included dabigatran 150 mg bid as a useful
alternative to warfarin (75 mg bid with creatinine clearance
15–30 mL/min). Consideration of individuals’ abilities to comply
with bid dosing, availability of anticoagulation monitoring facilities,
preference, and cost is recommended when deciding to treat
with dabigatran rather than warfarin. The update suggests that,
because of the non-haemorrhagic side effects of dabigatran,
patients already treated with warfarin with excellent INR
control may derive little beneﬁt from switching. In contrast to
the US, however, the 150 mg bid and 110 mg bid doses were
approved in Canada and the EU.
56,57 The CCS 2010 guidelines
recommend that most patients should receive dabigatran
(150 mg bid) in preference to warfarin.
12 Unlike in the USA,
the CCS 2010 guidelines also recommend the 110 mg dose for
patients with decreased renal function, low body weight, or an
increased risk of major bleeding.
A RE-LY subanalysis assessed the treatment effects of dabigatran
compared with warfarin for secondary prevention in patients with
prior stroke/TIA.
58 Consistent with the main study, both dabiga-
tran doses were associated with lower rates of stroke/systemic
embolism than warfarin (RR 0.84 for 110 mg and 0.75 for
150 mg). Once again, compared with warfarin, the rate of major
bleeding was signiﬁcantly lower with the 110 mg bid dose [RR
0.66 (95% CI 0.48–0.90)], and the higher dose showed no signiﬁ-
cant difference [RR 1.01 (95% CI 0.77–1.34)].
58 A network
meta-analysis also indirectly compared dabigatran treatment with
dual-antiplatelet therapy (ASA plus clopidogrel) for stroke preven-
tion in patients with AF.
59 The 150 mg dabigatran dose was pre-
dicted to signiﬁcantly reduce the risk of all stroke by 61%
compared with dual-antiplatelet therapy (95% CI 0.21–0.72).
The 110 mg dabigatran dose was estimated to reduce all stroke
risk [RR 0.55 (95% CI 0.30–1.00)] with a signiﬁcant reduction in
ischaemic stroke risk of 46% (95% CI 0.33–0.87), compared with
dual-antiplatelet therapy. There was no signal of an increase in
intracranial or extracranial haemorrhage with dabigatran
compared with dual-antiplatelet therapy. Within the EU, the rec-
ommended dose of dabigatran is 150 mg bid, but a lower,
110 mg bid dose should be used in elderly patients (age ≥80
years) or those taking verapamil, and considered in patients with
high bleeding risk, particularly in the presence of moderate renal
impairment (creatinine clearance 30–50 mL/min). The drug
should not be given to patients with severe renal impairment
(creatinine clearance ,30 mL/min).
60
An extension of the RE-LY study, known as RELY-ABLE, is
currently underway to assess the long-term safety of dabigatran
in patients with AF (www.clinicaltrials.gov, NCT00808067).
Patients who participated in RE-LY will receive further treatment
for up to 28 months; at the time of writing, the estimated
primary completion date (i.e. the ﬁnal data collection date for
the primary outcome measure of major bleeding) is April 2013.
Other direct thrombin inhibitors in atrial ﬁbrillation
AZD0837 is another direct thrombin inhibitor in development.
Phase II dose-ranging studies of AZD0837 extended-release
[150–450 mg once daily (od)] and immediate-release (150 or
350 mg bid) formulations report that it is generally well tolerated
in patients with non-valvular AF.
61,62 At the time of writing, it is
not known if a phase III trial is planned.
Oral direct Factor Xa inhibitors
In the search for effective oral anticoagulants, targeting factors
‘upstream’ from thrombin in the coagulation pathway, and thus
inhibiting its generation, has become a prime focus. Factor Xa is
of particular interest, given that it is the point where both the
intrinsic and extrinsic coagulation pathways converge. Several
oral direct Factor Xa inhibitors have been developed, a number
of which have been approved or are currently in the advanced
stages of testing in patients with AF.
Rivaroxaban
Rivaroxaban is a novel, oral, direct Factor Xa inhibitor. A 10 mg
oral dose has a reported absolute bioavailability of 80–100%;
elimination from the plasma occurs with terminal half-lives of
5–9 h in young individuals and 11–13 h in the elderly.
63–65
Two-thirds of the drug undergoes metabolic degradation in the
liver (half of which is excreted renally and half via the faecal
route); one-third is eliminated renally as unchanged drug.
66,67
The Rivaroxaban Once daily, oral, direct Factor Xa inhibition
Compared with vitamin K antagonism for prevention of stroke
and Embolism Trial in Atrial Fibrillation (ROCKET AF) completed
in late 2010. This phase III, double-blind, double-dummy study was
designed to assess the efﬁcacy and safety of rivaroxaban compared
with adjusted-dose warfarin for the prevention of stroke and
non-CNS systemic embolism (the composite primary efﬁcacy end-
point) in patients with non-valvular AF at increased risk of
stroke.
39,40 Patients were required to have prior stroke, TIA, or
systemic embolism, or two or more of the following risk factors
for study inclusion: clinical heart failure and/or left ventricular
J.-P. Bassand 320ejection fraction ≤35%, hypertension, age ≥75 years, or diabetes
mellitus (Table 3). Patients were given rivaroxaban 20 mg od with
oral warfarin placebo od (target sham INR 2.5, range 2.0–3.0),
or oral warfarin od (target INR 2.5, range 2.0–3.0) plus oral rivar-
oxaban placebo od. Patients with impaired renal function (esti-
mated creatinine clearance 30–49 mL/min) at randomization
received a lower dose of rivaroxaban (15 mg od). The study was
powered to determine non-inferiority of rivaroxaban compared
with warfarin for prevention of the primary efﬁcacy endpoint.
The test for non-inferiority was conducted in the per-protocol
population for the period when patients were receiving study
drug.
39,40 If non-inferiority was met, the possibility of superiority
would then be assessed in the safety population while receiving
study drug. Sensitivity analyses in the intention-to-treat (ITT)
population were also performed. Over 14 000 patients were
randomized at 1100 sites across 45 countries.
40
The mean CHADS2 score for patients who underwent ran-
domization was 3.5; 55% of patients had had a previous stroke, sys-
temic embolism, or TIA.
40 Rivaroxaban was indeed found to be
non-inferior to warfarin (Table 3). Furthermore, the subsequent
analysis in the safety population reported rivaroxaban to be
superior to warfarin while on treatment for the same endpoint
[hazard ratio (HR) 0.79 (95% CI 0.65–0.95); P ¼ 0.02]
(Table 3).
40 In the sensitivity analyses (which included analysis
periods both on and off study drug), rivaroxaban showed equival-
ence to warfarin (Table 3).
40 The investigators also reported a sig-
niﬁcant reduction in the composite secondary efﬁcacy endpoint of
vascular death, stroke, or embolism [HR 0.86 (95% CI 0.74–0.99);
P ¼ 0.034], for haemorrhagic stroke (P ¼ 0.024) and non-CNS sys-
temic embolism (P ¼ 0.003) with rivaroxaban in the safety popu-
lation.
40 Rates of major and non-major clinically relevant bleeding
events were similar between the two groups (Table 3), although
there were signiﬁcant reductions in the rates of intracranial haem-
orrhage (P ¼ 0.02), critical organ bleeding (P ¼ 0.007), and bleed-
ing-related death (P ¼ 0.003) in the rivaroxaban group.
40 In
contrast, there were signiﬁcant increases in the rates of haemo-
globin fall of ≥2 g/dL (P ¼ 0.02) or transfusion need (P ¼ 0.04)
in the rivaroxaban group compared with warfarin. Major bleeding
from a gastrointestinal site was also more common in the rivarox-
aban group compared with the warfarin group (3.2% vs. 2.2%; P ,
0.001).
40 Based on the ﬁndings of the ROCKET AF trial, rivaroxa-
ban was recently approved for stroke prevention in patients with
non-valvular AF in the US and in the EU.
68,69
In May 2011, the results of a subanalysis from those patients in
ROCKET AF with a prior stroke or TIA were presented at the
European Stroke Conference in Hamburg.
70,71 The relative efﬁcacy
and safety proﬁles of rivaroxaban compared with warfarin were
consistent with those seen in the overall trial population.
Another subgroup analysis assessed the efﬁcacy and safety of rivar-
oxaban in patients with moderate renal impairment (creatinine
clearance 30–49 mL/min) who received rivaroxaban 15 mg od.
72
Higher rates of stroke and overall bleeding were reported in
patients with moderate renal impairment versus those without,
but the subanalysis also found that the efﬁcacy and safety of rivar-
oxaban versus warfarin were consistent with those of the overall
ROCKET AF population receiving the 20 mg od dose. This is
reﬂected in the recent EU summary of product characteristics
for rivaroxaban, where the 15 mg od dose is recommended in
patients with moderate renal impairment (creatinine clearance
30–49 mL/min). It can also be used with caution in those with
severe renal impairment (creatinine clearance 15–29 mL/min),
but is not recommended in patients with creatinine clearance
,15 mL/min.
73
Apixaban
Apixaban is an oral, direct, selective Factor Xa inhibitor with an
oral bioavailability of  50%
74 and a half-life of  8–15 h in
healthy subjects.
75 Much of the drug is removed from the body
via the faeces, with  25% excreted renally.
75 The ﬁndings of
two phase III studies, Apixaban for Reduction In Stroke and
Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)
and Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in
Atrial Fibrillation Patients Who Have Failed or Are Unsuitable
for Vitamin K Antagonist Treatment (AVERROES), have recently
been reported (Table 3).
41–44 ARISTOTLE was a double-blind,
non-inferiority trial comparing apixaban 5 mg (or 2.5 mg in
selected patients) bid with warfarin (target INR 2.0–3.0) in
18 201 patients with AF and at least one risk factor for
stroke.
41,42 The mean CHADS2 score for patients in the ARISTO-
TLE trial was 2.1+1.1, with less than 20% of patients having a prior
stroke, TIA, or systemic embolism.
42 There was a signiﬁcant
reduction in the rate of stroke or systemic embolism with apixaban
compared with warfarin [HR 0.79 (95% CI 0.66–0.95); P ¼ 0.01
for superiority (ITT analysis)]. The investigators also reported sig-
niﬁcantly lower rates of major bleeding [HR 0.69 (95% CI 0.60–
0.80); P , 0.001], intracranial haemorrhage [HR 0.42 (95% CI
0.30–0.58); P , 0.001], and all-cause mortality [HR 0.89 (95% CI
0.80–0.99); P ¼ 0.047] with apixaban compared with warfarin.
42
Fewer myocardial infarctions and gastrointestinal bleeding events
were observed with apixaban versus warfarin, but these were
not statistically signiﬁcant (P ¼ 0.37).
42
AVERROES was a superiority trial in patients (n ¼ 5599) who
had failed or were unsuitable for VKA prophylaxis, comparing apix-
aban 5 mg (or 2.5 mg in selected patients) bid with ASA (81–
324 mg per day).
43,44 As with ARISTOTLE, the primary efﬁcacy
endpoint was the occurrence of stroke (ischaemic or haemorrha-
gic) or systemic embolism. AVERROES was terminated early fol-
lowing evidence from the interim analysis that apixaban was
more effective than ASA.
44 In AVERROES, the risk of primary end-
point occurrence was signiﬁcantly reduced with apixaban com-
pared with ASA [HR 0.45 (95% CI 0.32–0.62); P , 0.001]
(Table 3).
44 The major haemorrhage rate was not signiﬁcantly
higher with apixaban compared with ASA (Table 3). At the time
of writing, apixaban is not yet approved for stroke prevention in
patients with AF.
Edoxaban
Edoxaban (previously known as DU-176b) is an oral, direct, selec-
tive Factor Xa inhibitor also in clinical development for patients
with AF. A phase III trial, Effective Anticoagulation With Factor Xa
NextGenerationinAtrialFibrillation(ENGAGEAF-TIMI48),iscur-
rently underway (Table 3). This compares the efﬁcacy and safety of
twodosesofedoxaban(30and60 mgod)withwarfarinin  20 500
patients with AF and a moderate-to-high risk of stroke over 24
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45 The primary
endpoint is also the composite of stroke and systemic embolic
events. The trial is estimated to be completed in March 2012.
Other direct Factor Xa inhibitors
Betrixaban and darexaban (formerly YM150) also directly target
Factor Xa. Both were in the early stages of clinical testing in
patients with AF; however, it was announced in September 2011
that development of darexaban was to be stopped.
76
The EXPLORE-Xa phase II dose-ﬁnding study compared three
doses of betrixaban (40, 60, and 80 mg) with open-label, adjusted-
dose warfarin (INR 2.0–3.0) in patients with non-valvular AF or
atrial ﬂutter (n ¼ 508) (www.clinicaltrials.gov, NCT00742859).
77
The incidence of major and non-major clinically relevant bleeding
(the primary endpoint) was reported to be lower than warfarin
for the 40 mg dose and comparable to warfarin for the 60 and
80 mg doses. In a measure of drug activity, there was a small but
statistically signiﬁcant increase in D-dimer (a potential marker of
thrombosis) with the 40 mg dose compared with warfarin
(P ¼ 0.003). The investigators attributed this increase to the use
of warfarin as a comparator (as much-reduced D-dimer levels
would be expected following conventional warfarin therapy in
any case). Gastrointestinal disturbances (diarrhoea, nausea, and
constipation) were also more commonly reported among those
given the two higher doses of betrixaban vs. those on warfarin.
The safety and tolerability of darexaban in patients with AF were
investigated in the phase II OPAL-1 and OPAL-2 studies.
78,79 In the
OPAL-1 trial, four doses of darexeban (30, 60, 120, and 240 mg
od) were compared with open-label warfarin, administered over
12 weeks, in patients with non-valvular AF (n ¼ 448) in the Asia-
Paciﬁc region.
78 Similar incidences of major and non-major clinically
relevant bleeding to warfarin wereseen with the 30, 60, and 120 mg
doses of darexaban. No thromboembolic strokes were reported
duringthetreatmentperiod.InthelargerOPAL-2trial,1297patients
with non-valvular AF werealso randomized tovarious doses of dar-
exaban (15 mg bid, 30 mg od, 30 mg bid, 60 mg od, 60 mg bid, or
120 mg od) or adjusted-dose warfarin.
79 Across the full dose
range,darexabanshowedfewerbleedingeventscomparedwithwar-
farin. Annual event ratesfor thecompositeefﬁcacyendpoint (which
included ischaemic stroke, TIA, systemic embolism, acute coronary
syndrome, and/or any deaths) decreased as the dose increased
[1.1–6.7% per year (darexaban) vs. 1.8% per year (warfarin)].
79
Indirect Factor Xa inhibitors
There have also been moves in recent years to develop new par-
enterally administered indirect Factor Xa inhibitors. In the phase III
AMADEUS trial, idraparinux (2.5 mg weekly) was non-inferior to
adjusted-dose warfarin in patients with AF for the primary efﬁcacy
endpoint (all stroke and systemic embolism). However, the trial
was stopped early because of excess bleeding with idraparinux.
80
A biotinylated version, idrabiotaparinux, was also in clinical
development for patients with AF, but this has now ceased.
81
Conclusions
Current VKA therapy is highly effective at preventing stroke in
patients with non-valvular AF. However, this beneﬁt is offset by
the likelihood of bleeding associated with its use, as well as the
need for regular coagulation monitoring because of high inter-
and intra-subject variability and a sensitivity to drug interactions.
Acetylsalicylic acid is associated with fewer bleeding events
than VKA therapy but is far less efﬁcacious. In general, trials of
dual-antiplatelet therapy or combined antiplatelet and low- or
moderate-intensity VKA therapy in patients with AF have proved
disappointing.
Newer oral anticoagulants have the potential to simplify stroke
prevention in patients with AF. Despite differences in study design,
the phase III trials in patients with AF published to date for three of
the newer agents (RE-LY, ROCKET AF, and ARISTOTLE) drew
broadly similar conclusions.
82 Rates of stroke and systemic embo-
lism with the newer agents were at the very least comparable to
those of warfarin. Favourable bleeding proﬁles compared with war-
farin were reported across the trials, and there was an indication of
reduced mortality compared with warfarin (reaching statistical sig-
niﬁcance in the ARISTOTLE trial).
The newer agents may therefore overcome the limitations
associated with VKAs and provide an alternative to agents like war-
farin. Collectively, the new agents may also lead to improved
adherence to clinical guidelines when oral anticoagulation is the
recommended option (although the degree to which they are suc-
cessful in this may differ between the agents). This may in turn reap
substantial beneﬁts in terms of reducing the clinical and economic
burden of stroke.
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